The Relationship Between Traumatic Brain Injury and Dopamine (a Chemical in the Brain)

Phase

Condition

Traumatic Brain Injury

Memory Loss

Neurologic Disorders

Treatment

N/A

Clinical Study ID

NCT02015949

13HH1824

2013-004244-37

Ages 20-65
All Genders

Study Summary

Traumatic brain injury (TBI) is the most common cause of death and disability in young adults. Patients can experience significant problems with concentration, attention, and memory (so called 'cognitive impairments') following TBI. These cognitive impairments can drastically impact on a patient's well-being, and can lead to significant economic and social consequences. Roughly a quarter of TBI patients improve but an equal number deteriorate over time. The investigators know little about why patients vary so much in how they recover. Crucially, the investigators have no treatments to improve brain functioning or recovery after TBI.

Trials investigating ways of protecting the brain just after injury have been disappointing. An alternative strategy, however, is to improve the function of brain regions that remain intact, but that function inefficiently after TBI. The investigators know that dopamine (a chemical in the brain) is known to influence many brain functions and the investigators know that pathways in the brain that use dopamine are affected by TBI.

In humans, drugs that increase dopamine in the brain, such as methylphenidate, are sometimes used to enhance cognitive function after TBI, but the response to treatment can be highly variable between patients. Therefore, what is needed in the clinic is a way to target the use of these drugs to patients who are likely to respond.

In a single centre study, the investigators will use SPECT (Single Photon Emission Tomography) imaging to measure dopamine levels in the brain. MRI (Magnetic Resonance Imaging) scans will assess brain structure and function. The investigators will test whether treatment with methylphenidate improves cognitive functions in TBI patients who have ongoing cognitive problems, whether the mechanism involves a normalisation of brain functioning and whether brain dopamine levels can predict the magnitude of any improvement in symptoms.

Eligibility Criteria

Inclusion

Inclusion Criteria:

a diagnosis of a moderate-severe traumatic brain injury (as defined by the Mayo TBIseverity classification system) at least 3 months prior to recruitment into the study
age between 20 and 65 years
capable of giving written informed consent subjective complaint of cognitivedifficulties by the participant, treating clinician, or caregiver

Exclusion

Exclusion Criteria:

unwillingness or inability to follow the procedures required
significant neurological or psychiatric illness diagnosed prior to the TBI
family history of a first degree relative with a psychotic illness
currently participating in a clinical trial or has done so within 1 month beforescreening
use of any medication or substance that, in the opinion of the investigators, wouldinterfere with the study or compromise participant safety
history of a drug or other allergy that, in the opinion of the investigators,contraindicates their participation in the study
history of current or past drug or alcohol addiction
female participants who are breast feeding or pregnant (positive pregnancy test) orplan to become pregnant during the study
positive urine drug screen
contraindication to MRI scanning, assessed by a standard pre-MRI questionnaire
contraindication to the use of methylphenidate (including medications deemed to have apotentially serious interaction with methylphenidate as per the British NationalFormulary)
clinical evidence of motor symptoms of Parkinsonism as assessed by a Neurologist

Study Design

February 01, 2014

Connect with a study center

Imperial College
London,
United Kingdom
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.